These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35044590)

  • 1. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
    Chang HP; Li Z; Shah DK
    Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE).
    Chang HP; Cheung YK; Shah DK
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
    Chang HP; Cheung YK; Liu S; Shah DK
    Br J Clin Pharmacol; 2024 Jul; 90(7):1637-1655. PubMed ID: 38566392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
    Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
    Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
    Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
    AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
    Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
    J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.
    Singh AP; Shah DK
    Drug Metab Dispos; 2017 Nov; 45(11):1120-1132. PubMed ID: 28821484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
    Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
    Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S; Li Z; Bussing D; Shah DK
    Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species.
    Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
    Xenobiotica; 2024 Aug; 54(8):511-520. PubMed ID: 38647387
    [No Abstract]   [Full Text] [Related]  

  • 15. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs.
    Singh AP; Guo L; Verma A; Wong GG; Shah DK
    Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30823607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
    Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.
    Shah DK; King LE; Han X; Wentland JA; Zhang Y; Lucas J; Haddish-Berhane N; Betts A; Leal M
    AAPS J; 2014 May; 16(3):452-63. PubMed ID: 24578215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.